Furthermore, we reported that rituximab, an anti-CD20 monoclonal antibody targeting B cells, binds to SMPDL3b, thereby protecting podocytes from cytoskeleton disruption and apoptosis induced by treatment with sera from patients with recurrent FSGS [85]. Here, SMPDL3B is linked to focal segmental glomerulosclerosis.